GeneNews has launched ColonSentry in Ontario, the world's first commercially available blood-based test for colorectal cancer. This patient-friendly test has the potential to save thousands of lives by encouraging widespread screening, earlier detection of colorectal cancer, and targeted use of colonoscopy.
ColonSentry is based on award-winning technology, powered by the Sentinel Principle™, which uses blood samples to identify telltale RNA biomarkers for early disease. Since blood can be drawn easily and quickly, with very little discomfort and danger to the patient, blood-based biomarkers offer obvious advantages over traditional colorectal cancer testing.
ColonSentry has been developed to provide:
- a simply convenient first step for colorectal cancer testing;
- high patient acceptance;
- the benefits of genomics to colorectal cancer diagnostics;
- the opportunity to enrich the number of cancers detected by colonoscopy.
We chose colorectal cancer as our first commercial application of the Sentinel Principle™ because of the importance of the disease, the potential to significantly reduce morbidity and mortality due to enhanced patient compliance with a blood test vs. existing tests (which depend on endoscopy or collection of fecal material), and the large population base for which testing is warranted.